Helius Medical Technologies, Inc. (NASDAQ:HSDT) Short Interest Update

Helius Medical Technologies, Inc. (NASDAQ:HSDT) was the target of a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 111,800 shares, a growth of 208.0% from the February 29th total of 36,300 shares. Currently, 13.2% of the company’s stock are short sold. Based on an average daily trading volume, of 297,300 shares, the days-to-cover ratio is presently 0.4 days.

Helius Medical Technologies Trading Up 4.5 %

HSDT stock traded up $0.25 during trading on Thursday, hitting $5.85. 2,000 shares of the company’s stock were exchanged, compared to its average volume of 315,434. The business has a 50-day moving average price of $6.08 and a two-hundred day moving average price of $7.08. The stock has a market capitalization of $4.15 million, a price-to-earnings ratio of -0.26 and a beta of 1.41. Helius Medical Technologies has a 52-week low of $4.29 and a 52-week high of $14.44.

Wall Street Analyst Weigh In

Separately, Roth Mkm boosted their target price on Helius Medical Technologies to $24.00 and gave the stock a “buy” rating in a research note on Tuesday, March 5th.

Institutional Investors Weigh In On Helius Medical Technologies

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HSDT. Renaissance Technologies LLC lifted its stake in Helius Medical Technologies by 2,047.2% in the second quarter. Renaissance Technologies LLC now owns 227,600 shares of the company’s stock valued at $44,000 after buying an additional 217,000 shares during the last quarter. BlackRock Inc. lifted its stake in Helius Medical Technologies by 8,297.9% in the third quarter. BlackRock Inc. now owns 255,381 shares of the company’s stock valued at $71,000 after buying an additional 252,340 shares during the last quarter. Finally, Vanguard Group Inc. purchased a new stake in Helius Medical Technologies in the third quarter valued at approximately $108,000. Hedge funds and other institutional investors own 18.63% of the company’s stock.

Helius Medical Technologies Company Profile

Helius Medical Technologies, Inc, a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise.